How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

766 results for

Tumor Lysis Syndrome

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature (PubMed)

Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature 30241197 2019 03 04 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature. 1-4 10.1200/JGO.2016.007716 Socola Francisco F All authors: University of Arkansas

Full Text available with Trip Pro

2017 Journal of global oncology

3. Tumor Lysis Syndrome after Bilobectomy for Typical Carcinoid Tumor of the Lung. (PubMed)

Tumor Lysis Syndrome after Bilobectomy for Typical Carcinoid Tumor of the Lung. Tumor lysis syndrome is a life-threatening complication comprising hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia attributed to release of intracellular contents. Although traditionally associated with leukemia and lymphoma after chemotherapy, it is known to occur in solid malignancies. We herein report a rare case of this syndrome after resection of bulky carcinoid tumor of the lung.Copyright ©

2018 Annals of Thoracic Surgery

4. Rasburicase for adults with acute tumor lysis syndrome: a review of clinical and cost effectiveness and safety

Rasburicase for adults with acute tumor lysis syndrome: a review of clinical and cost effectiveness and safety Rasburicase for adults with acute tumor lysis syndrome: a review of clinical and cost effectiveness and safety Rasburicase for adults with acute tumor lysis syndrome: a review of clinical and cost effectiveness and safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Rasburicase for adults with acute tumor lysis syndrome: a review of clinical and cost effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions Rasburicase was found to lower uric acid levels in adult cancer patients who had, or were at risk for developing, hyperuricemia or tumour lysis syndrome (TLS). Rasburicase was found

2014 Health Technology Assessment (HTA) Database.

5. Spontaneous Tumor Lysis Syndrome

Spontaneous Tumor Lysis Syndrome Renal Fellow Network: Spontaneous Tumor Lysis Syndrome | | | | | Tuesday, February 21, 2017 Spontaneous Tumor Lysis Syndrome A 70 year old Ghanaian man was recently admitted under our care. He had been diagnosed with aggressive myelodysplasia 2 months previously after presenting with fatigue and abnormal blood results (WBC 50.3, platelets 130 and LDH 928 at the time of diagnosis). A plan was made for palliative chemotherapy. One month after his diagnosis he (...) at the time and he did not appear ‘uremic’ despite his renal dysfunction. Could any of this have been prevented if treatment for his hyperuricemia had been commenced earlier? I also learned: The nuances of spontaneous tumor lysis syndrome (often phosphate & K not hugely elevated). Rasburicase is contraindicated if glucose-6-phosphatase deficient (approximately 20% of Africans). The ‘undetectable’ result of urate after rasburicase administration to be due to in vitro activity of the drug in the blood

2017 Renal Fellow Network

6. A rare seizure: Tumor lysis syndrome after radiation therapy of a solid tumor. (PubMed)

A rare seizure: Tumor lysis syndrome after radiation therapy of a solid tumor. Tumor lysis syndrome (TLS) is an uncommon but life threatening condition seen in oncology patients. Due to its underlying pathophysiology, it is classically associated with hematologic malignancies following chemotherapeutic treatment. In this article, we present a case of TLS in the setting of two rare features: a solid tumor malignancy and the absence of recent chemotherapy. We briefly review risk factors

2017 American Journal of Emergency Medicine

7. Tumor lysis syndrome in a patient with ovarian yolk sac tumor (PubMed)

Tumor lysis syndrome in a patient with ovarian yolk sac tumorTumor lysis syndrome is an oncologic emergency with profound metabolic derangements.•Germ cell tumors with large disease burden increase the risk for tumor lysis syndrome.•Herein we present a case of tumor lysis syndrome prior to initiation of cytotoxic chemotherapy for ovarian yolk sac tumor.

Full Text available with Trip Pro

2017 Gynecologic Oncology Reports

8. Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults

Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults (FLORET) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2018 Clinical Trials

9. Urine xanthine crystals in tumor lysis syndrome. (PubMed)

Urine xanthine crystals in tumor lysis syndrome. Urine xanthine crystals are remarkably rare but can be observed by routine urine microscopy. We report the results of a 67-year-old man with T-cell-prolymphocytic leukemia whose urine contained xanthine crystals after chemotherapy and prophylactic administration of febuxostat. Accumulation of xanthine was due to tumor lysis syndrome causing a massive release of DNA. The metabolized DNA caused an increase of xanthine, which was not readily

2018 Urology

10. Tumor lysis syndrome associated with docetaxel and carboplatin in a case with recurrent endometrial cancer (PubMed)

Tumor lysis syndrome associated with docetaxel and carboplatin in a case with recurrent endometrial cancer Tumor lysis syndrome (TLS) is an oncological life-threatening complication characterized by hyperuricemia, hyperphosphatemia, and hyperkalemia, which can lead to acute renal failure, cardiac arrhythmias, cardiac arrest and seizures. Although TLS is a rare complication in patients with non-hematological malignancy, the mortality rate of TLS in solid tumors is higher than (...) that in hematological malignancies. Acute renal injury is the most common cause of mortality associated with TLS in solid tumors. We report a case of TLS following chemotherapy for a recurrent uterine serous carcinoma. In this case, we speculated that the cause of death might be a pulmonary tumor embolism caused by TLS.

Full Text available with Trip Pro

2018 Gynecologic Oncology Reports

11. Evaluation and characterization of tumor lysis syndrome before and after chemotherapy among pediatric oncology patients in Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. (PubMed)

Evaluation and characterization of tumor lysis syndrome before and after chemotherapy among pediatric oncology patients in Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. Tumor lysis syndrome (TLS) is a life-threatening emergency disorder, caused by an abrupt release of intracellular metabolites after tumor cell death. It is characterized by a series of metabolic manifestations, especially hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia. The aim of this study (...) was to evaluate and characterize the incidence of tumor lysis syndrome among pediatric oncology patients before and after treatment.Hospital based prospective cohort study was conducted for 6 months on 61 newly diagnosed pediatric oncology patients. Socio-demographic data was collected by interview administered questionnaire. Patients were followed and the physical diagnosis, imaging and laboratory results were interpreted by senior physicians. Data was entered to and analyzed by SPSS version 23.Among 61

Full Text available with Trip Pro

2018 BMC Hematology

12. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. (PubMed)

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. Early data on venetoclax-containing regimens for the treatment of chronic lymphocytic leukemia (CLL) show promising results with deep remissions, but are hampered by potential risk for tumor lysis syndrome (TLS). Whether optimal duration of venetoclax treatment can be guided by minimal residual disease (MRD) is currently unknown. To study whether TLS risk can

Full Text available with Trip Pro

2018 Blood advances

13. Treatment-naïve spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: An unusual suspect. (PubMed)

Treatment-naïve spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: An unusual suspect. Tumor lysis syndrome (TLS) is a potentially fatal condition defined both by laboratory and clinical criteria. It is caused by the catabolism of tumor cells which leads to considerable release and elevated levels of phosphate, potassium and uric acid in the bloodstream. These electrolyte derangements predispose patients to renal tubule uric acid precipitation, acute kidney injury (...) , arrhythmias, neuromuscular irritability and even seizures. Although this phenomenon is well described with hematological malignancies, it is also known to occur among solid tumors. We present a rare case of treatment-naïve spontaneous TLS that occurred in a 69-year-old male with metastatic prostate adenocarcinoma with hyperkalemia, hyperuricemia, hyperphosphatemia, hypocalcemia, elevated liver enzymes, AKI and hemodynamic instability. Despite our best resuscitative efforts with intravenous hydration

2017 American Journal of Emergency Medicine

14. Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies (PubMed)

Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies Abstract Tumor lysis syndrome (TLS) is a potentially life-threatening emergency that can develop rapidly after the release of intracellular contents from lysed malignant cells. The advent of novel and targeted therapies that have improved tumor-killing efficacy has the potential to increase the risk of TLS when used as part of front-line therapy. A recent review of TLS risk in patients with hematologic malignancies treated

Full Text available with Trip Pro

2017 Journal of the advanced practitioner in oncology

15. Tumor Lysis Syndrome in Patients with Hematological Malignancies (PubMed)

Tumor Lysis Syndrome in Patients with Hematological Malignancies Tumor lysis syndrome is a metabolic complication that may follow the initiation of cancer therapy. It commonly occurs in hematological malignant patients particularly non-Hodgkin's lymphoma and acute leukemia due to chemotherapy or spontaneously. It is characterized by a biochemical abnormality such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia and its clinical outcome is directly related to these biochemical (...) abnormalities. Prevention and treatment of tumor lysis syndrome depend on immediate recognition of patients at risk. Therefore, identifying patients at risk and prophylactic measures are important to minimize the clinical consequences of tumor lysis syndrome. Patients with low risk should receive hydration and allopurinol. On the other hand patients with high risk should receive hydration and rasburicase in an inpatient setting. It is important to start therapy immediately, to correct all parameters before

Full Text available with Trip Pro

2017 Journal of oncology

16. Spontaneous tumor lysis syndrome in small cell lung cancer (PubMed)

Spontaneous tumor lysis syndrome in small cell lung cancer Tumor lysis syndrome is a set of metabolic disturbances that can be seen during the destruction of tumor cells and is an oncologic and metabolic emergency. The syndrome is rare in those with solid tumors, and even more rare in those with solid tumors who have not yet received chemotherapy. We present a case of tumor lysis syndrome in a patient with small cell lung cancer.

Full Text available with Trip Pro

2017 Proceedings (Baylor University. Medical Center)

17. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase (PubMed)

Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase Tumor lysis syndrome (TLS) is a potentially life-threatening condition that occurs in oncologic and hematologic patients with large tumor burden, either due to cytotoxic therapy or, less commonly, spontaneously because of massive tumor cell lysis. TLS is clinically characterized by acute renal failure, hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. While limited options are available (...) manifestations of TLS. For this review, a comprehensive literature search using the term "tumor lysis syndrome" and/or "rasburicase" was performed considering articles listed in MEDLINE. Incidence, prevention, and therapy of TLS with a special focus on the role of rasburicase are discussed. We evaluated 120 relevant articles including 35 case reports, 32 clinical trials, and 14 meta-analyses.

Full Text available with Trip Pro

2017 OncoTargets and therapy

18. Spontaneous Tumor Lysis Syndrome in Small Cell Lung Cancer (PubMed)

Spontaneous Tumor Lysis Syndrome in Small Cell Lung Cancer Tumor lysis syndrome (TLS) is a life-threatening oncologic complication caused by the lysis of a vast number of malignant cells resulting in metabolic derangements and organ dysfunction. TLS can occur spontaneously before initiation of any therapies often referred to as spontaneous tumor lysis syndrome (STLS), or shortly after the induction of chemotherapy, radiotherapy, or cytolytic antibody therapy. TLS is vastly seen in patients (...) with hematological malignancies with high rapid cell turnover rates such as Burkitt lymphoma, acute myelogenous leukemia, and acute lymphocytic leukemia, and is rarely observed in solid tumors. However, TLS can occur in solid tumors, and there are multiple reports in the literature on the occurrence of TLS in various solid tumors. In this article, we report a case of STLS in small cell lung cancer followed by a brief review of the occurrence of TLS and STLS in small cell lung cancer.

Full Text available with Trip Pro

2017 Cureus

19. Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer (PubMed)

Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer Tumor lysis syndrome (TLS) is a life-threatening oncological emergency, with most cases occurring in hematological malignancies following the initiation of treatment. However, on rare occasions, TLS may occur in solid tumors as well. In the present case study, the case is reported of a 56-year-old African-American man who presented with a recent diagnosis of prostate cancer, abdominal pain, elevated transaminases (...) , renal insufficiency, hyperkalemia, and hyperuricemia, consistent with spontaneous TLS in the setting of metastatic prostate cancer. A computed tomography scan of the patient's abdomen demonstrated diffuse metastatic tumor burden. Following treatment with allopurinol, rasburicase, and initiation of anti-androgen therapy for the prostate cancer, the patient's TLS laboratory results normalized, however, his renal functions continued to decline. TLS is rare in solid tumors, and particularly rare

Full Text available with Trip Pro

2017 Molecular and clinical oncology

20. Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature (PubMed)

Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature This case report describes a spontaneous tumor lysis syndrome due to a rare solid tumor.A 65-year-old white woman had tumor lysis syndrome, which represent a dangerous oncological emergency. This syndrome occurs usually with a hematological tumor, but in this case our patient had a solid tumor, which was a rare extraskeletal osteosarcoma, localized in her pelvic region. She also had lung metastases (...) and bilateral hydronephrosis. After spontaneous tumor lysis syndrome, she had acute renal insufficiency, which was treated with hemodialysis and successively with rasburicase, Kayexalate (sodium polystyrene sulfonate), and febuxostat.Tumor lysis syndrome represents an oncological emergency, which must be suspected and treated as soon as possible.

Full Text available with Trip Pro

2017 Journal of medical case reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>